about
Targeting Aggressive Cancer Stem Cells in GlioblastomaThe MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomideGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaSynergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunityDistress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma.Protocol for the Care-IS Trial: a randomised controlled trial of a supportive educational intervention for carers of patients with high-grade glioma (HGG).First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trialStatins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural patients with cancer in Western Australia: a study protocolComparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.Soluble mesothelin-related protein--a blood test for mesothelioma.The potential role of exercise in neuro-oncologyMalignant pleural mesothelioma: an update on diagnosis and treatment options.Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Systemic therapy for advanced hepatocellular carcinoma: a review.Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.Optimization of response classification criteria for patients with malignant pleural mesothelioma.Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer.Combined chemoimmunotherapy of solid tumours: improving vaccines?Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.Disease volumes as a marker for patient response in malignant pleural mesothelioma.Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomesDexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies.Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesotheliomaChemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk?Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.Contribution of the immune system to the chemotherapeutic response.Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target.
P50
Q26799983-0464DB85-4B6B-45C7-83F6-F449FDA7A732Q27853156-D1EA99E2-3126-4B3D-8977-76DAC2492D97Q28394028-B904A851-6B53-413F-89D3-812FB3634A3DQ28486600-E1A3E928-E4DC-4790-BE9E-36DFD602E543Q30151616-D5B34C2F-1EB7-4CD7-ADB5-A71DF683DD46Q30202300-9AB0857A-43F2-4CD1-8AAD-FC5198AD8A64Q30946452-0B92AA8D-0799-4500-AB59-A8378322E6A5Q33391857-F3B1BD87-E912-4CFE-A81F-13CBF57D63DEQ33502208-6EA7032F-9D3B-4531-B770-89A5D92446B1Q33805073-BAD868DF-25DE-41EB-B434-16A2958343A1Q33874477-8969A967-5992-4DC3-96D6-A3D1CEC4BE5EQ34004787-7BC58830-CE63-4ECA-9444-D597A878DC78Q34197547-93B6EEA0-C4C5-4B22-B5A9-0D6A1C44400FQ34239292-7DCE36E0-DDAD-4527-AC53-AC21307C08E3Q34425780-CE1B99C5-DB43-4C93-8D6A-FB00427ED311Q34473328-DB80D3F0-339C-4C02-A69B-06E2DE720CD2Q34513958-ADE94DA4-CCCF-4DED-9D04-9648F9B77C99Q35741879-8FD36E63-99A7-483E-85F3-31D55452E685Q35799065-A251F0C0-F76B-45AC-9989-0115E4DB9C7EQ35804764-F5719AFE-6A9A-4CF2-94B7-C3FFFD2F9D64Q35869292-C72856B4-C6E1-49EC-B20E-B041EBB7C990Q36060666-6358DEFC-EAE4-4012-B066-80A60DB4F2A2Q36322856-C4B8C701-8CB1-4858-89D3-1FB434648CB5Q36432125-6CA9D7EB-4362-43E6-AEC6-ADA87B027C81Q36605604-1CB3D657-4A23-4ABD-BCFD-780F34A04AB8Q36611703-0D6FF6A6-057B-4624-902C-A06A891FEC5BQ36646087-4B355643-25B0-45C0-9CC3-3C821B0656B9Q36667439-5A0DC0E4-A5F7-47EE-AA95-8020E1727091Q36685687-9494602D-8E33-403A-811D-8BBBECC834C8Q36702389-51C9E95D-9D49-4BE6-AB26-B67B22E3B5CFQ36711060-05FD04C5-0942-455E-8D7B-298F665244C9Q36821113-EFCF1CA2-727A-4C2E-9270-036A80A5005AQ37214250-B572F843-6618-4BA2-ADB8-F869FFBEF4CDQ37473603-7F41CA34-DCB8-42D5-93EB-C57C90B229E2Q37527750-617B76DC-492E-4374-8EA9-9B757CC2BDAEQ37533221-AA7C54DC-413B-4717-9D75-49B621E9402BQ37746144-94A8F306-7414-47DC-8621-26A18BD75383Q37764507-368A4782-55F4-4D50-B9F7-EFDB3A84B859Q37832967-97B29CE0-61DD-4CC0-BB83-217F903967C0Q38287518-1047233D-B2FE-4264-A681-481C3116E91F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna K. Nowak
@ast
Anna K. Nowak
@en
Anna K. Nowak
@es
type
label
Anna K. Nowak
@ast
Anna K. Nowak
@en
Anna K. Nowak
@es
altLabel
A Nowak
@en
AK Nowak
@en
Anna Nowak
@en
prefLabel
Anna K. Nowak
@ast
Anna K. Nowak
@en
Anna K. Nowak
@es
P1053
B-2487-2013
P106
P1153
7201664962
P21
P31
P3829
P496
0000-0002-9317-9526